Aspire Biopharma Announces Reverse Stock Split
ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a...
Clinical Trial
Zomedica Announces “Fourth Friday at Four” Webinar on January 23rd Focused on Digital Innovation & Technology-Driven Growth
January session to highlight Zomedica's expanding digital capabilities and long-term innovation strategy ANN ARBOR, MI / ACCESS Newswire / January...
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026
CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx,...
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) today announced that it will...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression...
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide...
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement...
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system...
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025...
New Clinical Trial Shows Seed’s DS-01® Reduces Bloating, Improves Regularity, and Enhances Digestive Quality of Life
Findings reflect the rigorous clinical standards behind DS-01®'s position as the #1 digestive health probiotic in the U.S.LOS ANGELES, Jan....
Brillio Recognized as a Leader in HFS Horizons: Life Sciences Service Providers 2025 Report
Recognition underscores Brillio's AI-driven innovation and measurable impact on health outcomes, cost, patient experience, and equityDALLAS, Jan. 13, 2026 /PRNewswire/...
The Mark Foundation for Cancer Research Announces 2026 Emerging Leader Awards, Committing $3.75 Million to Next-Generation Oncology Breakthroughs
Since 2018, more than $40 million has been granted to support outstanding cancer research projects by early-career scientistsNEW YORK, Jan....
CluePoints Appoints New Chief People Officer to Support Next Phase of Global Growth
KING OF PRUSSIA, Pa., Jan. 13, 2026 /PRNewswire/ -- CluePoints, provider of leading statistical and AI-driven software solutions, has appointed...
Ability Center brings Cognoa’s Canvas Dx to Saudi Arabia, giving families faster, more precise autism evaluations in early childhood
NEWPORT BEACH, Calif., Jan. 13, 2026 /PRNewswire/ -- Cognoa and The Ability Center today announced the exclusive availability in Saudi...
Aignostics Announces New State-of-the-Art Pathology Foundation Model
Atlas 2 sets new industry standard and achieves best-in-class performance and computational efficiencyBERLIN and NEW YORK, Jan. 13, 2026 /PRNewswire/...
Vericel Announces Preliminary 2025 Financial Results and Business Updates
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI...
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
Partnership enables broader adoption of FemaSeed through a trusted community health provider serving a large, engaged patient populationATLANTA , Jan....